查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1542427

全球癌症单株抗体市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测

Global Cancer Monoclonal Antibodies Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 179 Pages | 商品交期: 最快1-2个工作天内

价格

全球癌症单株抗体市场需求预计将从2023年的929.4亿美元达到近4,354.3亿美元的市场规模，2024-2032年研究期间的复合年增长率为18.72%。

癌症单株抗体 (mAb) 是实验室生产的分子，经过改造可特异性结合癌细胞或参与癌症生长的蛋白质。这些抗体源自单一细胞克隆，针对癌细胞表面或内部存在的独特抗原，为癌症治疗提供精确的治疗选择。它们标记癌细胞以供免疫系统破坏、阻断生长讯号或将细胞毒性剂直接递送至肿瘤部位。单株抗体是癌症标靶治疗不可或缺的一部分，可治疗多种癌症，包括乳癌、淋巴瘤和白血病。它们的特异性和针对性方法有助于最大限度地减少对健康细胞的损害，使它们成为肿瘤学的关键进步。

市场动态

在全球癌症盛行率不断上升的推动下，癌症单株抗体市场正在迅速扩大。与传统治疗相比，单株抗体提供的标靶治疗由于其精确性和副作用减少而越来越受到青睐。这种精准医疗方法符合个人化医疗保健的成长趋势，进一步推动市场成长。生物技术的进步和对癌症生物学了解的加深为开发创新单株抗体创造了新的机会。研究人员不断发现新的标靶和途径，创造出具有更高功效和安全性的下一代单株抗体。联合疗法的发展，即单株抗体与化疗或免疫疗法等其他治疗方法一起使用，也扩大了它们的治疗潜力和癌症单株抗体的市场范围。

公共和私营部门对癌症研究和开发的投资不断增加是推动癌症单株抗体市场的另一个关键因素。製药公司正在积极寻求新的单株抗体和临床试验，产生稳定的潜在疗法。此外，对早期癌症检测和预防的日益重视预计将有助于更多地采用基于单株抗体的诊断方法。然而，高昂的开发和生产成本可能会阻碍市场成长。研究、开发和製造单株抗体所需的大量投资可能会限制可及性并影响整体市场扩张。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球癌症单株抗体市场的各个细分市场进行了包容性评估。癌症单株抗体产业的成长和趋势为这项研究提供了整体方法。

市场区隔

癌症单株抗体市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按类型

  • 人性化
  • 人类
  • 嵌合体
  • 鼠类

按申请

  • 血癌
  • 乳癌
  • 肺癌
  • 黑色素瘤
  • 大肠直肠癌
  • 肝癌
  • 其他的

按最终用户

  • 医院
  • 研究所
  • 其他的

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲癌症单株抗体市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。癌症单株抗体市场的主要参与者包括罗氏有限公司、百时美施贵宝公司、默克公司、葛兰素史克公司、强生公司、安进公司、诺华公司、阿斯特捷利康公司、礼来公司和公司，艾伯维。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：癌症单株抗体 - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 按类型分類的市场吸引力分析
    • 市场吸引力分析：依应用分类
    • 最终用户的市场吸引力分析
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球癌症单株抗体市场分析：按类型

  • 按类型概述
  • 按类型分析历史和预测数据
  • 人性化
  • 人类
  • 嵌合体
  • 鼠类

第 6 章：全球癌症单株抗体市场分析：依应用分类

  • 概述：按应用
  • 历史和预测数据分析：按应用
  • 血癌
  • 乳癌
  • 肺癌
  • 黑色素瘤
  • 大肠直肠癌
  • 肝癌
  • 其他的

第 7 章：全球癌症单株抗体市场分析：按最终用户分类

  • 最终用户概述
  • 最终用户的历史和预测数据分析
  • 医院
  • 研究所
  • 其他的

第 8 章：全球癌症单株抗体市场分析：依地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区按国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲按国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 9 章：癌症单株抗体公司的竞争格局

  • 癌症单株抗体市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 10 章：公司简介

  • 顶级公司市占率分析
  • 市场集中度
  • F. Hoffmann-La Roche Ltd.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Bristol Myers Squibb Co.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Merck & Co.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • GlaxoSmithKline Plc
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Johnson & Johnson
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Amgen Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Novartis AG
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • AstraZeneca Plc
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Eli Lilly And Company
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • AbbVie
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

Product Code: VMR11216177

The global demand for Cancer Monoclonal Antibodies Market is presumed to reach the market size of nearly USD 435.43 Billion by 2032 from USD 92.94 Billion in 2023 with a CAGR of 18.72% under the study period 2024-2032.

Cancer monoclonal antibodies (mAbs) are laboratory-produced molecules engineered to bind specifically to cancer cells or proteins involved in cancer growth. Derived from a single clone of cells, these antibodies target unique antigens present on or within cancer cells, offering precise therapeutic options for cancer treatment. They mark cancer cells for destruction by the immune system, block growth signals, or deliver cytotoxic agents directly to the tumor site. Monoclonal antibodies are integral to targeted cancer therapies, addressing various cancers, including breast, lymphoma, and leukemia. Their specificity and targeted approach help minimize damage to healthy cells, making them a pivotal advancement in oncology.

MARKET DYNAMICS

The cancer monoclonal antibodies market is expanding rapidly, fueled by the propelling prevalence of cancer worldwide. Monoclonal antibodies offer targeted therapy that is increasingly preferred due to its precision and reduced side effects compared to traditional treatments. This precision medicine approach aligns with the growing trend towards personalized healthcare, further boosting market growth. Advancements in biotechnology and an improved understanding of cancer biology are creating new opportunities for developing innovative monoclonal antibodies. Researchers continuously discover novel targets and pathways, creating next-generation mAbs with enhanced efficacy and safety profiles. The development of combination therapies, where monoclonal antibodies are used alongside other treatments such as chemotherapy or immunotherapy, also expands their therapeutic potential and cancer monoclonal antibodies market reach.

The increasing investment in cancer research and development by the public and private sectors is another key factor driving the cancer monoclonal antibodies market. Pharmaceutical companies are actively pursuing new mAbs and clinical trials, leading to a steady pipeline of potential therapies. Additionally, the growing emphasis on early cancer detection and prevention is expected to contribute to the increased adoption of monoclonal antibody-based diagnostics. However, high development and production costs may hinder market growth. The substantial investment required to research, develop, and manufacture monoclonal antibodies can limit accessibility and affect overall market expansion.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Cancer Monoclonal Antibodies. The growth and trends of Cancer Monoclonal Antibodies industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Cancer Monoclonal Antibodies market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

  • Humanized
  • Human
  • Chimeric
  • Murine

By Application

  • Blood Cancer
  • Breast Cancer
  • Lung Cancer
  • Melanoma
  • Colorectal Cancer
  • Liver Cancer
  • Others

By End-user

  • Hospitals
  • Research Institutes
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cancer Monoclonal Antibodies market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cancer Monoclonal Antibodies market include F. Hoffmann-La Roche Ltd., Bristol Myers Squibb Co., Merck & Co., GlaxoSmithKline Plc, Johnson & Johnson, Amgen Inc., Novartis AG, AstraZeneca Plc, Eli Lilly And Company, AbbVie. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. CANCER MONOCLONAL ANTIBODIES - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Type
    • 3.7.2 Market Attractiveness Analysis By Application
    • 3.7.3 Market Attractiveness Analysis By End-user
    • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS BY TYPE

  • 5.1. Overview By Type
  • 5.2. Historical and Forecast Data Analysis By Type
  • 5.3. Humanized Historic and Forecast Sales By Regions
  • 5.4. Human Historic and Forecast Sales By Regions
  • 5.5. Chimeric Historic and Forecast Sales By Regions
  • 5.6. Murine Historic and Forecast Sales By Regions

6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS BY APPLICATION

  • 6.1. Overview By Application
  • 6.2. Historical and Forecast Data Analysis By Application
  • 6.3. Blood Cancer Historic and Forecast Sales By Regions
  • 6.4. Breast Cancer Historic and Forecast Sales By Regions
  • 6.5. Lung Cancer Historic and Forecast Sales By Regions
  • 6.6. Melanoma Historic and Forecast Sales By Regions
  • 6.7. Colorectal Cancer Historic and Forecast Sales By Regions
  • 6.8. Liver Cancer Historic and Forecast Sales By Regions
  • 6.9. Others Historic and Forecast Sales By Regions

7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS BY END-USER

  • 7.1. Overview By End-user
  • 7.2. Historical and Forecast Data Analysis By End-user
  • 7.3. Hospitals Historic and Forecast Sales By Regions
  • 7.4. Research Institutes Historic and Forecast Sales By Regions
  • 7.5. Others Historic and Forecast Sales By Regions

8. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2 North America By Segment Sales Analysis
    • 8.3.3 North America By Country Sales Analysis
    • 8.3.4 United States Sales Analysis
    • 8.3.5 Canada Sales Analysis
    • 8.3.6 Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2 Europe By Segment Sales Analysis
    • 8.4.3 Europe By Country Sales Analysis
    • 8.4.4 United Kingdom Sales Analysis
    • 8.4.5 France Sales Analysis
    • 8.4.6 Germany Sales Analysis
    • 8.4.7 Italy Sales Analysis
    • 8.4.8 Russia Sales Analysis
    • 8.4.9 Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2 Asia Pacific By Segment Sales Analysis
    • 8.5.3 Asia Pacific By Country Sales Analysis
    • 8.5.4 China Sales Analysis
    • 8.5.5 India Sales Analysis
    • 8.5.6 Japan Sales Analysis
    • 8.5.7 South Korea Sales Analysis
    • 8.5.8 Australia Sales Analysis
    • 8.5.9 South East Asia Sales Analysis
    • 8.5.10 Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2 Latin America By Segment Sales Analysis
    • 8.6.3 Latin America By Country Sales Analysis
    • 8.6.4 Brazil Sales Analysis
    • 8.6.5 Argentina Sales Analysis
    • 8.6.6 Peru Sales Analysis
    • 8.6.7 Chile Sales Analysis
    • 8.6.8 Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2 Middle East & Africa By Segment Sales Analysis
    • 8.7.3 Middle East & Africa By Country Sales Analysis
    • 8.7.4 Saudi Arabia Sales Analysis
    • 8.7.5 UAE Sales Analysis
    • 8.7.6 Israel Sales Analysis
    • 8.7.7 South Africa Sales Analysis
    • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE CANCER MONOCLONAL ANTIBODIES COMPANIES

  • 9.1. Cancer Monoclonal Antibodies Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10. COMPANY PROFILES OF CANCER MONOCLONAL ANTIBODIES INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. F. Hoffmann-La Roche Ltd.
    • 10.3.1 Company Overview
    • 10.3.2 Company Revenue
    • 10.3.3 Products
    • 10.3.4 Recent Developments
  • 10.4. Bristol Myers Squibb Co.
    • 10.4.1 Company Overview
    • 10.4.2 Company Revenue
    • 10.4.3 Products
    • 10.4.4 Recent Developments
  • 10.5. Merck & Co.
    • 10.5.1 Company Overview
    • 10.5.2 Company Revenue
    • 10.5.3 Products
    • 10.5.4 Recent Developments
  • 10.6. GlaxoSmithKline Plc
    • 10.6.1 Company Overview
    • 10.6.2 Company Revenue
    • 10.6.3 Products
    • 10.6.4 Recent Developments
  • 10.7. Johnson & Johnson
    • 10.7.1 Company Overview
    • 10.7.2 Company Revenue
    • 10.7.3 Products
    • 10.7.4 Recent Developments
  • 10.8. Amgen Inc.
    • 10.8.1 Company Overview
    • 10.8.2 Company Revenue
    • 10.8.3 Products
    • 10.8.4 Recent Developments
  • 10.9. Novartis AG
    • 10.9.1 Company Overview
    • 10.9.2 Company Revenue
    • 10.9.3 Products
    • 10.9.4 Recent Developments
  • 10.10. AstraZeneca Plc
    • 10.10.1 Company Overview
    • 10.10.2 Company Revenue
    • 10.10.3 Products
    • 10.10.4 Recent Developments
  • 10.11. Eli Lilly And Company
    • 10.11.1 Company Overview
    • 10.11.2 Company Revenue
    • 10.11.3 Products
    • 10.11.4 Recent Developments
  • 10.12. AbbVie
    • 10.12.1 Company Overview
    • 10.12.2 Company Revenue
    • 10.12.3 Products
    • 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Type (USD MN)
  • Humanized Market Sales By Geography (USD MN)
  • Human Market Sales By Geography (USD MN)
  • Chimeric Market Sales By Geography (USD MN)
  • Murine Market Sales By Geography (USD MN)
  • Analysis By Application (USD MN)
  • Blood Cancer Market Sales By Geography (USD MN)
  • Breast Cancer Market Sales By Geography (USD MN)
  • Lung Cancer Market Sales By Geography (USD MN)
  • Melanoma Market Sales By Geography (USD MN)
  • Colorectal Cancer Market Sales By Geography (USD MN)
  • Liver Cancer Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By End-user (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Research Institutes Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Cancer Monoclonal Antibodies Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Cancer Monoclonal Antibodies Report
  • Market Research Process
  • Market Research Methodology
  • Global Cancer Monoclonal Antibodies Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Type
  • Market Attractiveness Analysis By Application
  • Market Attractiveness Analysis By End-user
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Type (USD MN)
  • Humanized Market Sales By Geography (USD MN)
  • Human Market Sales By Geography (USD MN)
  • Chimeric Market Sales By Geography (USD MN)
  • Murine Market Sales By Geography (USD MN)
  • Global Market Analysis By Application (USD MN)
  • Blood Cancer Market Sales By Geography (USD MN)
  • Breast Cancer Market Sales By Geography (USD MN)
  • Lung Cancer Market Sales By Geography (USD MN)
  • Melanoma Market Sales By Geography (USD MN)
  • Colorectal Cancer Market Sales By Geography (USD MN)
  • Liver Cancer Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By End-user (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Research Institutes Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.